and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

And there’s no questioning that Biogen is facing big challenges as another of its top drugs – spinal muscular atrophy treatment Spinraza (nusinersen) – faces competition from Novartis’ one ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Biogen Pharmachem Industries Ltd share price was down by -2.91% from the previous closing price of ₹1.03. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spinraza treatment may help restore lipid balance to the cerebrospinal fluid (CSF) of children with SMA, according to a small ...

Pre-market: 4:33:02 am GMT-5 ...

Dividend announcements are not available.